How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash
The market for priority review vouchers is holding steady at $125 million per deal.
That’s what BioMarin just received for its PRV, sold off to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
